Log in to your Inderes Free account to see all free content on this page.
Create account

Xintela

0.26 SEK

+4.44 %

Less than 1K followers

XINT

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+4.44 %
-10.38 %
-11.60 %
-8.80 %
-3.00 %
-47.29 %
+0.16 %
-85.75 %
-88.69 %

Xintela operates in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes on the surface of cells, which enables the identification of stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.

Read more
Market cap
223.07M SEK
Turnover
24.38K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
29.5.
2026

Interim report Q1'26

28.8.
2026

Interim report Q2'26

27.11.
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Xintela: Moving forward with XSTEM - VH Corp

* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated studies * We keep our fair value of SEl 1.04 per share Xintela’s year-end report did not reveal any substantial surprises. The recent rights issue and loan...

Xintela
Third party research

Xintela: Extending the financial runway - VH Corp

* The rights issue added MSEK 42 before loan offset * Fenja Capital II provides loan facility of MSEK 20 * After dilution, our fair value amounts to SEK 1.04 (1.28) per share Xintela’s recent rights issue was subscribed to 58 per cent, corresponding ...

Xintela
Third party research

Xintela: Focus on study results and financing - VH Corp

• Final study results support XSTEM’s disease-modifying potential in OA • Rights issue of MSEK 72.8 announced at SEK 0.26 per share • Q&A with CEO Evy Lundgren Åkerlund on the new Targinta collaboration Xintela released its Q3 report on November 4 instead...

Xintela
Third party research

Xintela: Awaiting final follow-up data - VH Corp

• The 24-month follow-up data to be reported by the end of Q3 • The GMP production facility is generating revenue • Adjusted for dilution, our fair value amounts to SEK 1.28 per share Xintela’s half-year report did not reveal any surprises. As announced...

Xintela

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.